The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H., Cigarroa, J. E., Cleveland, J. C., Conti, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,115
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Self-citationStangier, J., Haertter, S., Liesenfeld, K.-H., Wienen, W., Feuring, M., Clemens, A., & Ryn, J. V. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0758 · Cited by 1,382
Stangier, J., Rathgen, K., Stähle, H., Gansser, D., & Roth, W. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02899.x · Cited by 887
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Kubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 640
PERZBORN, E., STRASSBURGER, J., WILMEN, A., POHLMANN, J., ROEHRIG, S., SCHLEMMER, K.-H., & STRAUB, A. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01166.x · Cited by 590
Ogata, K., Mendell‐Harary, J., Tachibana, M., Masumoto, H., Oguma, T., Kojima, M., & Kunitada, S. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009351883 · Cited by 453
Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants
Cuker, A., Siegal, D. M., Crowther, M. A., & Garcia, D. A. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.065 · Cited by 449
Self-citationAssessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor
Martinoli, J.-L., LeFlem, L., Guinet, C., Plu-Bureau, G., Depasse, F., Perzborn, E., & Samama, M. M. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-03-0176 · Cited by 449
Stangier, J., Stähle, H., Rathgen, K., & Fuhr, R. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847010-00005 · Cited by 427
Ezekowitz, M. D., Reilly, P. A., Nehmiz, G., Simmers, T. A., Nagarakanti, R., Parcham-Azad, K., Pedersen, K. E., Lionetti, D. A., Stangier, J., & Wallentin, L. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.06.034 · Cited by 419
Ruff, C. T., Giugliano, R. P., Braunwald, E., Morrow, D. A., Murphy, S. A., Kuder, J. F., Deenadayalu, N., Jarolim, P., Betcher, J., Shi, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61943-7 · Cited by 405
Wang, Z., Frost, C., Shenker, A., & Barrett, Y. C. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-05-0328 · Cited by 356
Connolly, S., Patel, I., Salazar, D., Rohatagi, S., Mendell, J., Kastrissios, H., Jin, J., Kunitada, S., & Weitz, J. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-01-0066 · Cited by 341
Stangier, J., & Clemens, A. (2009) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029609343004 · Cited by 337
Mueck, W., Lensing, A. W. A., Agnelli, G., Decousus, H., Prandoni, P., & Misselwitz, F. (2011) · Clinical Pharmacokinetics · doi:10.2165/11595320-000000000-00000 · Cited by 327
Robert, S., Chatelain, C., Douxfils, J., Mullier, F., Chatelain, B., & Dogné, J.-M. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-11-0804 · Cited by 325
FURUGOHRI, T., ISOBE, K., HONDA, Y., KAMISATO‐MATSUMOTO, C., SUGIYAMA, N., NAGAHARA, T., MORISHIMA, Y., & SHIBANO, T. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03064.x · Cited by 301
Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
HILLARP, A., BAGHAEI, F., FAGERBERG BLIXTER, I., GUSTAFSSON, K. M., STIGENDAL, L., STEN‐LINDER, M., STRANDBERG, K., & LINDAHL, T. L. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04098.x · Cited by 288
Frost, C., Nepal, S., Wang, J., Schuster, A., Byon, W., Boyd, R. A., Yu, Z., Shenker, A., Barrett, Y. C., Mosqueda‐Garcia, R., et al. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12106 · Cited by 286
Borris, L. C., Dahl, O. E., Haas, S., Huisman, M. V., Kakkar, A. K., Kälebo, P., Muelhofer, E., Misselwitz, F., Eriksson, B. I., & Mueck, W. (2008) · Thrombosis and Haemostasis · doi:10.1160/th07-12-0714 · Cited by 273
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays
Baghaei, F., Blixter, I. F., Gustafsson, K., Stigendal, L., Sten-Linder, M., Strandberg, K., Hillarp, A., Lindahl, T., & and from the expert group on coagulation of the External Quality Assurance in Laboratory Medicine in Sweden (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-06-0342 · Cited by 269
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
Stangier, J., & Feuring, M. (2012) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32834f1b0c · Cited by 265
Baglin, T., Hillarp, A., Tripodi, A., Elalamy, I., Buller, H., & Ageno, W. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12149 · Cited by 256
Douxfils, J., Mullier, F., Loosen, C., Chatelain, C., Chatelain, B., & Dogné, J.-M. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.09.004 · Cited by 248
Mueck, W., Eriksson, B. I., Bauer, K. A., Borris, L., Dahl, O. E., Fisher, W. D., Gent, M., Haas, S., Huisman, M. V., Kakkar, A. K., et al. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847030-00006 · Cited by 243
Contant, G., Spiro, T., Perzborn, E., Guinet, C., Gourmelin, Y., Flem, L., Rohde, G., Martinoli, J., Samama, M., & Laboratories, F. T. R. A.-F. X. C. A. F. T. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-06-0391 · Cited by 232
Hawes, E. M., Deal, A. M., Funk‐Adcock, D., Gosselin, R., Jeanneret, C., Cook, A. M., Taylor, J. M., Whinna, H. C., Winkler, A. M., & Moll, S. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12308 · Cited by 231
GEROTZIAFAS, G. T., ELALAMY, I., DEPASSE, F., PERZBORN, E., & SAMAMA, M. M. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02429.x · Cited by 159
Tamigniau, A., Châtelain, B., Chatelain, C., Wallemacq, P. E., Dogné, J., Mullier, F., & Douxfils, J. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-04-0274 · Cited by 150
Becker, R. C., Yang, H., Barrett, Y., Mohan, P., Wang, J. J. J., Wallentin, L. C., & Alexander, J. H. (2011) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-011-0591-8 · Cited by 148
Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests
Asmis, L. M., Alberio, L., Angelillo‐Scherrer, A., Korte, W. C., Mendez, A., Reber, G., Seifert, B., Stricker, H. J., Tsakiris, D. A., & Wuillemin, W. A. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.06.031 · Cited by 140
Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants
Dias, J. D., Norem, K., Doorneweerd, D. D., Thurer, R. L., Popovsky, M. A., & Omert, L. (2015) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0170-oa · Cited by 138
Fukuda, T., Honda, Y., Kamisato, C., Shibano, T., & MORISHIMA, Y. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-09-0668 · Cited by 132
Zafar, M. U., Vorchheimer, D. A., Gaztañaga, J., Velez, M., Yadegar, D., Moreno, P., Kunitada, S., García‐Pagán, J. C., Fuster, V., & Badimon, J. (2007) · Thrombosis and Haemostasis · doi:10.1160/th07-04-0312 · Cited by 124
Frost, C. E., Song, Y. J., Barrett, Y. C., Wang, J. J. J., Pursley, J. M., Boyd, R. A., & LaCreta, F. P. (2014) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s61131 · Cited by 122
Tripodi, A., Chantarangkul, V., GUINET, C., & Samama, M. M. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04106.x · Cited by 119
Liesenfeld, K., Schäfer, H. G., Trocóniz, I. F., Tillmann, C., Eriksson, B. I., & Stangier, J. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02667.x · Cited by 118
Mendell, J., Tachibana, M., Shi, M., & Kunitada, S. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010370974 · Cited by 117
Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays
Flaujac, C., Delavenne, X., Quenet, S., Horellou, M., Laporte, S., Siguret, V., Lecompte, T., & Gouin‐Thibault, I. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-06-0470 · Cited by 116
Girgis, I. G., Patel, M. R., Peters, G. R., Moore, K. T., Mahaffey, K. W., Nessel, C. C., Halperin, J. L., Califf, R. M., Fox, K. A. A., & Becker, R. C. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.288 · Cited by 111
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review
Cuker, A. C., & Husseinzadeh, H. D. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1185-7 · Cited by 111
Self-citationDager, W. E., Gosselin, R. C., Kitchen, S., & Dwyre, D. M. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r179 · Cited by 111
Performance of coagulation tests in patients on therapeutic doses of rivaroxaban
Hawes, E. M., Deal, A. M., Adcock, D. M., et al. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-10-0871 · Cited by 108
Rohde, G., Stratmann, G., Hesse, C., Herth, N., Schwers, S., Perzborn, E., Lindhoff‐Last, E., & Mani, H. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-12-0832 · Cited by 98
Helin, T., Pakkanen, A., Lassila, R., & Joutsi‐Korhonen, L. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.198788 · Cited by 88
Avecilla, S. T., Ferrell, C., Chandler, W. L., et al. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpau7oqm0srpzq · Cited by 85
Interpretation of Point-of-care INR Results in Patients Treated with Dabigatran
van Ryn, J., Baruch, L., & Clemens, A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.10.017 · Cited by 83
Samama, M. M., Contant, G., Spiro, T. E., et al. (2012) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029611426282 · Cited by 83
Influence of dabigatran and rivaroxaban on routine coagulation assays: A nationwide Belgian survey
Bailleul, E., Châtelain, B., Demulder, A., Devreese, K. M. J., Douxfils, J., Jochmans, K., Mullier, F., Wijns, W., Soumali, M. R., Coucke, W., et al. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-02-0161 · Cited by 82
Bonar, R. A., Favaloro, E. J., Mohammed, S., Pasalic, L., Sioufi, J., & MARSDEN, K. A. (2015) · Pathology · doi:10.1097/pat.0000000000000252 · Cited by 77
Skeppholm, M., Al-Aieshy, F., Berndtsson, M., Al‐Khalili, F., Rönquist-Nii, Y., Söderblom, L., Östlund, A., Pohanka, A., Antović, J. P., & Malmström, R. E. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.04.030 · Cited by 73
Dinkelaar, J., Molenaar, P. J., Ninivaggi, M., et al. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12236 · Cited by 72
Gosselin, R. C., Francart, S. J., Hawes, E. M., Moll, S., Dager, W. E., & Adcock, D. M. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015578451 · Cited by 71
Samama, M. M., Mendell, J., Guinet, C., Flem, L. L., & Kunitada, S. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.07.026 · Cited by 71
Laboratory Measurements of the Oral Direct Factor Xa Inhibitor Edoxaban
MORISHIMA, Y., & Kamisato, C. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcpq2njd3pxftug · Cited by 71
Determination of Rivaroxaban in Human Plasma Samples
Harenberg, J., Erdle, S., Marx, S., & Krämer, R. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1301415 · Cited by 66
Delavenne, X., Moracchini, J., Laporte, S., Mismetti, P., & Basset, T. (2011) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2011.09.018 · Cited by 63
Determination of Dabigatran in Human Plasma Samples
Harenberg, J., Christina, G., Marx, S., et al. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0031-1300947 · Cited by 62
Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests
Halbmayer, W., Weigel, G., Quehenberger, P., Tomasits, J., Haushofer, A. C., Aspoeck, G., Loacker, L., Schnapka-Köpf, M., Goebel, G., & Griesmacher, A. (2012) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2011-0888 · Cited by 62
Arachchillage, D. J., Mackie, I. J., Efthymiou, M., Isenberg, D. A., Machin, S. J., & Cohen, H. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12917 · Cited by 61
Direct oral anticoagulant drug level testing in clinical practice: A single institution experience
Martin, K. A., & Moll, S. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.04.019 · Cited by 61
Xu, X. S., Moore, K. T., Burton, P. B. J., Stuyckens, K., Mueck, W., Rossenu, S., Plotnikov, A. N., Gibson, C. M., & Vermeulen, A. (2012) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04181.x · Cited by 56
On the monitoring of dabigatran treatment in “real life” patients with atrial fibrillation
Skeppholm, M., Hjemdahl, P., Antović, J. P., Muhrbeck, J., Eintrei, J., Rönquist-Nii, Y., Pohanka, A., Beck, O., & Malmström, R. E. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.06.016 · Cited by 51
Association rate constants rationalise the pharmacodynamics of apixaban and rivaroxaban
Jourdi, G., Siguret, V., Martin, A., Golmard, J., Godiér, A., Samama, C. M., Gaussem, P., Gouin‐Thibault, I., & Bonniec, B. L. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-10-0877 · Cited by 50
Molenaar, P. J., Dinkelaar, J., & Leyte, A. (2012) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2012-0055 · Cited by 49
How the Direct Oral Anticoagulant Apixaban Affects Thrombin Generation Parameters
Tripodi, A., Padovan, L., Chantarangkul, V., Scalambrino, E., Testa, S., & Peyvandi, F. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.03.032 · Cited by 48
Comparison of Methods to Determine Rivaroxaban anti-factor Xa activity
Rathbun, S. W., Tafur, A. J., Grant, R. P., Esmon, N. L., Mauer, K., & Marlar, R. A. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.11.017 · Cited by 48
Multimodal assessment of non‐specific hemostatic agents for apixaban reversal
Martin, A., Gouin‐Thibault, I., Siguret, V., Mordohay, A., Samama, C. M., Gaussem, P., Bonniec, B. L., & Godiér, A. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12830 · Cited by 48
The in vitro anticoagulant effect of rivaroxaban in children
Attard, C., Monagle, P., Kubitza, D., & Ignjatović, V. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.07.009 · Cited by 45
Measurement and Reversal of Prophylactic and Therapeutic Peak Levels of Rivaroxaban
Körber, M. K., Langer, E., Ziemer, S., et al. (2013) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029613494468 · Cited by 45
Gosselin, R. C., Funk, D. M. A., Taylor, J., Francart, S. J., Hawes, E. M., Friedman, K. D., & Moll, S. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0750-oa · Cited by 43
Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation
Burghaus, R., Coboeken, K., Gaub, T., Kuepfer, L., Sensse, A., Siegmund, H., Weiß, W. W., Mueck, W., & Lippert, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017626 · Cited by 41
A Novel Prothrombin Time Assay for Assessing the Anticoagulant Activity of Oral Factor Xa Inhibitors
Barrett, Y. C., Wang, Z., & Knabb, R. M. (2012) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612441859 · Cited by 39
Harenberg, J., Marx, S., Krämer, R., Giese, C., & Weiß, C. (2011) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e328349f1d6 · Cited by 36
Assessing the anticoagulant effect of dabigatran in children: An in vitro study
Dietrich, K. D., Stang, L. J., van Ryn, J., & Mitchell, L. G. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.01.017 · Cited by 32
Yamamura, N., Stangier, J., Reilly, P. A., Clemens, A., & Härtter, S. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-08-0551 · Cited by 32
An evaluation of oral dabigatran etexilate pharmacokinetics and pharmacodynamics in hemodialysis
Wilson, J.-A. S., Goralski, K. B., Soroka, S. D., Morrison, M. J., Mossop, P., Sleno, L., Wang, Y., & Anderson, D. R. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.335 · Cited by 29
Douxfils, J., Châtelain, B., Hjemdahl, P., et al. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.02.020 · Cited by 26
Wolzt, M., Gouya, G., Kapiotis, S., Becka, M., Mueck, W., & Kubitza, D. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.05.019 · Cited by 13
Honda, Y., & MORISHIMA, Y. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.03.001 · Cited by 9
Cited by
Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant
Douketis, J. D., Spyropoulos, A. C., Duncan, J., Carrier, M., Le Gal, G., Tafur, A. J., Vanassche, T., Verhamme, P., Shivakumar, S., Gross, P. L., et al. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.2431 · Cited by 532
Perioperative Management of Antithrombotic Therapy
Douketis, J. D., Spyropoulos, A. C., Murad, M. H., Arcelus, J. I., Dager, W. E., Dunn, A. S., Fargo, R. A., Levy, J. H., Samama, C. M., Shah, S. H., et al. (2022) · CHEST · doi:10.1016/j.chest.2022.07.025 · Cited by 450
Tomaselli, G. F., Mahaffey, K. W., Cuker, A., Dobesh, P. P., Doherty, J. U., Eikelboom, J. W., Florido, R., Gluckman, T. J., Hucker, W. J., Mehran, R., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.04.053 · Cited by 397
Self-citationTomaselli, G. F., Mahaffey, K. W., Cuker, A., Dobesh, P. P., Doherty, J. U., Eikelboom, J. W., Florido, R., Hucker, W., Mehran, R., Messé, S. R., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.1085 · Cited by 345
Self-citationReversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum
Cuker, A., Burnett, A., Triller, D., Crowther, M., Ansell, J., Van Cott, E. M., Wirth, D., & Kaatz, S. (2019) · American Journal of Hematology · doi:10.1002/ajh.25475 · Cited by 315
Self-citation
Metadata
- Authors
- Samuelson, B. T., Cuker, A., Siegal, D. M., Crowther, M., & Garcia, D. A.
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 151
- Issue
- 1
- Pages
- 127-138
- ISSN
- 0012-3692 (ISSN-L)
- OpenAlex
- W2520740086
- Cited by
- 345
- References
- 87
- FWCI
- 25.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.